Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1089 participants.

Also called NCT02128932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,089 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02128932
  • EudraCT 2013-004392-12
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial The lancet. Diabetes & endocrinology, 2017-05 DOI, PubMed 28344112
  • Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29687620, PMC6099273 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766634, PMC6099440 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Croatia, France, Germany, India, Mexico, Netherlands, North Macedonia, Puerto Rico, Romania, Slovakia, Slovenia, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02128932. Randomized; no masking; primary purpose treatment. Start 2014-08-04 (actual); primary completion 2015-09-03 (actual). Results posted on 2018-03-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Acronym
SUSTAIN™ 4
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02128932
Content hash
df3d4e829fae7d2bc1f09f2a3366e0904b36186eaab4e2c106ea12fa502a89bf